Supplementary Figures S1 - S6 from Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer

Gunderson, Andrew; Kaneda, Megan M.; Tsujikawa, Takahiro; Nguyen, Abraham V.; Affara, Nesrine I.; Ruffell, Brian; Gorjestani, Sara; Liudahl, Shannon M.; Truitt, Morgan; Olson, Peter; Kim, Grace; Hanahan, Douglas; Tempero, Margaret A.; Sheppard, Brett C.; Irving, Bryan; Chang, Betty; Varner, Judith A.; Coussens, Lisa M.

doi:10.1158/2159-8290.22530965.v1

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical role of BTK extends beyond its effects on normal and malignant B cells. PI3Kg can activate BTK to promote phospholipase C (PLC) g-dependent signaling in hematopoietic cells, including myeloid cells (69). A recent study suggested a regulatory role for BTK in T-cell activation.…”

Section: Btk Inhibitors (Btki)mentioning

confidence: 99%

The magic of small-molecule drugs during ex vivo expansion in adoptive cell therapy

et al. 2023

View full text Add to dashboard Cite

In the past decades, advances in the use of adoptive cellular therapy to treat cancer have led to unprecedented responses in patients with relapsed/refractory or late-stage malignancies. However, cellular exhaustion and senescence limit the efficacy of FDA-approved T-cell therapies in patients with hematologic malignancies and the widespread application of this approach in treating patients with solid tumors. Investigators are addressing the current obstacles by focusing on the manufacturing process of effector T cells, including engineering approaches and ex vivo expansion strategies to regulate T-cell differentiation. Here we reviewed the current small-molecule strategies to enhance T-cell expansion, persistence, and functionality during ex vivo manufacturing. We further discussed the synergistic benefits of the dual-targeting approaches and proposed novel vasoactive intestinal peptide receptor antagonists (VIPR-ANT) peptides as emerging candidates to enhance cell-based immunotherapy.

show abstract

Section: Btk Inhibitors (Btki)mentioning

confidence: 99%